ID: ALA5278656

Max Phase: Preclinical

Molecular Formula: C25H28N6O3S

Molecular Weight: 492.61

Representations

Canonical SMILES:  COc1cccc(S(=O)(=O)n2ccc3cnc(Nc4ccc(N5C[C@@H](C)N[C@@H](C)C5)cc4)nc32)c1

Standard InChI:  InChI=1S/C25H28N6O3S/c1-17-15-30(16-18(2)27-17)21-9-7-20(8-10-21)28-25-26-14-19-11-12-31(24(19)29-25)35(32,33)23-6-4-5-22(13-23)34-3/h4-14,17-18,27H,15-16H2,1-3H3,(H,26,28,29)/t17-,18+

Standard InChI Key:  GLRBJDQXLPBXND-HDICACEKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 492.61

Molecular Weight (Monoisotopic): 492.1944

AlogP: 3.61

#Rotatable Bonds: 6

Polar Surface Area: 101.38

Molecular Species: BASE

HBA: 9

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.09

CX LogP: 3.81

CX LogD: 2.13

Aromatic Rings: 4

Heavy Atoms: 35

QED Weighted: 0.42

Np Likeness Score: -1.27

References

1. Xie W, Yang S, Liang L, Wang M, Zuo W, Lei Y, Zhang Y, Tang W, Lu T, Chen Y, Jiang Y..  (2022)  Discovery of 2-Amino-7-sulfonyl-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Potent Reversible FGFR Inhibitors with Gatekeeper Mutation Tolerance: Design, Synthesis, and Biological Evaluation.,  65  (24.0): [PMID:36480917] [10.1021/acs.jmedchem.2c01420]

Source

Source(1):

• Scientific Literature